Mind Medicine (MindMed), Inc.

As of September 19, 2025, Mind Medicine (MindMed), Inc. shows a mildly bullish technical trend with positive momentum indicators, having outperformed the S&P 500 year-to-date and over the past year, though caution is advised due to mixed longer-term performance.

As of September 9, 2025, Mind Medicine (MindMed), Inc. shows a mildly bullish trend with strong weekly indicators, despite mixed signals from monthly metrics, and has outperformed the S&P 500 year-to-date and over the past year, but underperformed in longer time frames.

As of June 18, 2025, the market trend is neutral with mixed signals: weekly indicators show bullish momentum, while daily moving averages and monthly trends suggest short-term weakness, reflecting a lack of strong conviction in either direction.

As of March 2022, the management team of Mind Medicine (MindMed), Inc. includes Executive Chairman and Co-CEO Stephen Hurst, President and Director Miriam Wernli, and Co-CEO Jamon Rahn, along with independent directors Perry Dellelce, Stanley Glick, Bruce Linton, and Brigid Makes.

Mind Medicine (MindMed), Inc. is a neuro-pharmaceutical company focused on developing psychedelic-inspired medicines for health and wellness. It has a market cap of approximately $506.96 million and reported a net profit loss of $23 million as of March 2025.

As of Jun 18, Mind Medicine (MindMed), Inc. has a market capitalization of 506.96 million and reported net sales of 0.00 million with a net profit of -77.62 million over the last four quarters. Shareholder's funds were 241.45 million, and total assets were 302.15 million.